Search

Displaying results 1221 - 1230 of 10000 in total
  1. Indication

    Marginal Zone Lymphoma (MZL)

    go.drugbank.com/conditions/DBCOND0110322
    Drugs: Ibrutinib · Lenalidomide · Zanubrutinib
    Synonyms: Marginal Zone Lymphomas, Marginal Zone Lymphoma
  2. Indication

    Refractory Marginal Zone Lymphoma

    go.drugbank.com/conditions/DBCOND0092876
    Drugs: Lisocabtagene maraleucel · Zanubrutinib
    Synonyms: Marginal zone lymphoma refractory, Refractory Marginal Zone Lymphoma
  3. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    [A275507, A275509] It serves as an advanced option to address the clinical challenge of endocrine-resistant breast cancer subtypes. … [L56181] It is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and ESR1-mutated advanced or metastatic breast cancer

    Categories: Selective Estrogen Receptor Degraders
  4. Drug

    Janssen COVID-19 Vaccine

    go.drugbank.com/drugs/DB15857
    ApprovedInvestigational

    The Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745] … Follow-up preclinical studies in rhesus monkeys[A220058] showed that the Ad26 vaccine produced a robust response and provided near perfect protection in nasal swabs and bronchoalveolar lavage following

  5. Drug

    Mumps virus strain B level jeryl lynn live antigen

    go.drugbank.com/drugs/DB10316
    ApprovedInvestigational

    Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.

    Mixtures: M-M-R II, M-M-R II
  6. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with … [A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury.

  7. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    from week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period. … [L49469] This approval was based on positive results demonstrated in the open-label, single-arm Phase 3 BENEGENE-2 study, where the annualized bleeding rate (ABR) was observed to be 1.3 for the 12 months

  8. Drug

    Anthralin

    go.drugbank.com/drugs/DB11157
    Approved

    Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. … Anthralin is also known as dithranol. It is a main active ingredient in topical skin formulations for the treatment of psoriasis.

  9. Target

    Leucine-rich repeat-containing G protein-coupled receptor 5

    go.drugbank.com/bio_entities/BE0010835
    TargetHumans

    Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle.

    Polypeptides: Leucine-rich repeat-containing G protein-coupled receptor 5Synonyms: G protein-coupled receptor 49, G protein-coupled receptor 67
  10. Drug

    Corifollitropin alfa

    go.drugbank.com/drugs/DB09066
    ApprovedInvestigational

    In July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for this drug. … The increased in the number of eggs retrieved under corifollitropin alfa regimen represents the elevated effectiveness of this drug, however, warns at the same time against the possibility of an increased